$IBRX (ImmunityBio) can become the next short-term rocket/long-term investment
ImmunityBio's Anktiva, an IL-15 immunotherapy developed by billionaire oncologist Patrick Soon-Shiong, has clinically proven efficacy in bladder cancer and ongoing success in glioblastoma trials. Short-term catalyst: 127M shorted shares (38.8% of float) requiring cover within days; long-term upside driven by FDA resubmission, EMA approval expansion, and Q4 earnings report with target prices of $11-$24.
At post $6.93·Now $8.29+19.6% since postedas of Oct 30, 4:45 PM ET
1d-5.3%
3d-4.5%
1w-14.2%
1m+19.3%
3m+22.8%
6m+10.2%
1y—
“balls deep into this, been stacking position for a few days”
Did a thing - IBRX
IBRX is entering a high-growth phase driven by ANKTIVA's successful commercialization and regulatory expansion. The drug achieved 700% YoY revenue growth in 2025, secured accelerated approval in Saudi Arabia for both bladder and lung cancer, and has a de-risked pipeline with BCG-naïve trials ahead of schedule, positioning the company for substantial TAM expansion.
At post $5.52·Now $8.29+50.2% since postedas of Oct 30, 4:45 PM ET
1d—
3d—
1w+16.8%
1m+7.7%
3m+31.3%
6m+40.0%
1y—
IBRX (ImmunityBio) - Great squeeze potential
IBRX has exceptional short squeeze setup with ~40% float shorted, ~10 days to cover, and rising borrow costs, while the company releases multiple positive catalysts (lung cancer data, Saudi FDA approval, upcoming glioblastoma/CAR-NK data). Strong fundamentals including 424% YoY revenue growth and $257M cash eliminate bankruptcy risk, making a break above $3.00 a potential explosive move.
At post $3.02·Now $8.29+174.5% since postedas of Oct 30, 4:45 PM ET
1d+30.8%
3d+82.8%
1w+129.1%
1m+96.9%
3m+151.7%
6m+157.9%
1y—
$IBRX - Possibly the greatest squeeze candidate in r/pennystocks history
IBRX is a squeeze candidate with positive clinical results for its lung cancer drug and strategic partnerships with Saudi biotech interests. The company has a structural imbalance with 136% of the 89M share float shorted, creating potential for a significant short squeeze as shares accumulate on a steady uptrend.
At post $2.82·Now $8.29+194.0% since postedas of Oct 30, 4:45 PM ET
1d+7.1%
3d+95.7%
1w+129.8%
1m+134.8%
3m+158.9%
6m+191.5%
1y—